These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32664839)

  • 1. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
    Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
    Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
    Bambury RM; Morris PG
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
    Corso CD; Bindra RS
    Semin Radiat Oncol; 2016 Oct; 26(4):281-98. PubMed ID: 27619250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
    Rezaei V; Rabiee A; Khademi F
    J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
    Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
    Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU
    Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in glioblastoma multiforme: Integrating therapy and pathology perspectives.
    Shahcheraghi SH; Alimardani M; Lotfi M; Lotfi M; Uversky VN; Guetchueng ST; Palakurthi SS; Charbe NB; Hromić-Jahjefendić A; Aljabali AAA; Gadewar MM; Malik S; Goyal R; El-Tanani M; Mishra V; Mishra Y; Tambuwala MM
    Pathol Res Pract; 2024 May; 257():155285. PubMed ID: 38653089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
    Ung N; Yang I
    J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
    Gainer JL; Sheehan JP; Larner JM; Jones DR
    J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatment strategies for glioblastoma multiforme.
    Carlsson SK; Brothers SP; Wahlestedt C
    EMBO Mol Med; 2014 Nov; 6(11):1359-70. PubMed ID: 25312641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.